Label: information for the user
Narine Repetabs5mg/120mg prolonged-release tablets
loratadine/pseudoephedrine sulfate
Read this label carefully before starting to takethis medication, as it contains important information for you.
What is Narine Repetabs
Narine Repetabs tablets contain a combination of two medications, an antihistamine (loratadine) and a decongestant (pseudoephedrine).
How Narine Repetabs works
Narine Repetabs helps to reduce the symptoms of allergy or common cold by blocking the effects of a substance called “histamine”, which the body produces when it is allergic to something. Decongestants help to clear nasal congestion.
When to use Narine Repetabs
Narine Repetabs tablets relieves symptoms associated with seasonal allergic rhinitis (hay fever), such as sneezing, runny or itchy nose or eyes when accompanied by nasal congestion in adults and adolescents 12 years and older.
Do not take Narine Repetabs
Do not take Narine Repetabs
Warnings and precautions
Certain diseases may make you abnormally sensitive to the pseudoephedrine decongestant contained in this medication.
Consult your doctor or pharmacist before starting to take Narine Repetabs:
Inform your doctor if you notice or are diagnosed with any of the following:
One of the active ingredients of Narine Repetabs, pseudoephedrine sulfate, may cause dependence and large amounts of pseudoephedrine sulfate may be toxic.
If you develop a generalized fever rash associated with pustules, stop taking Narine Repetabs and contact your doctor or seek medical attention immediately. See section 4.
Abdominal pain or rectal bleeding may occur with the use of Narine Repetabs due to ischemic colitis. If these gastrointestinal symptoms appear, stop taking Narine Repetabs and contact your doctor or seek medical attention immediately. See section 4.
Narine Repetabs may cause a reduction in blood flow to the optic nerve. If you experience sudden vision loss, stop taking Narine Repetabs and contact your doctor or seek medical attention immediately. See section 4.
There have been reports of reversible posterior encephalopathy syndrome (RPES) and reversible cerebral vasoconstriction syndrome (RCVS) after the use of medications containing pseudoephedrine. RPES and RCVS are rare diseases that may involve a reduction in blood flow to the brain. Stop using Narine Repetabs immediately and seek medical attention if you experience symptoms that may be signs of RPES or RCVS (see section 4 "Possible side effects").
Children
Do not give this medication to children under 12 years of age.
Taking Narine Repetabs with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription.
Taking Narine Repetabs with alcohol
Narine Repetabs has not been shown to potentiate the effects of alcohol.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Do not take Narine Repetabs if you are pregnant.
Breastfeeding
Do not take Narine Repetabs if you are breastfeeding.
Loratadine and pseudoephedrine are excreted in breast milk. There have been reports of a decrease in milk production in breastfeeding mothers using pseudoephedrine, a component of Narine Repetabs.
Driving and operating machinery
At the recommended dose, Narine Repetabs is not expected to cause drowsiness or decreased alertness. However, very rarely some people may experience drowsiness, which may affect their ability to drive or operate machinery.
Narine Repetabs contains lactose and saccharose
Narine Repetabs contains lactose and saccharose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Laboratory tests:This medication contains a component that may establish a positive analytical result for doping control.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
How to Take
Adults and adolescents 12 years of age or older:
The recommended dose is one Narine Repetabs prolonged-release tablet twice a day with a glass of water, regardless of meals. twice with a glass of water, regardless of meals.
This medication is taken orally. Swallow the tablet whole; do not crush, break, or chew the tablet before swallowing.
Do not take more Narine Repetabs tablets than recommended in this leaflet, or more frequently than recommended.
Do not take this medication for more than 10 consecutive days unless your doctor tells you otherwise.
If you take more Narine Repetabs than you should
If you take more Narine Repetabs than you should, consult your doctor or pharmacist immediately. Somnolence, palpitations, and headache have been reported with loratadine overdose, a component of Narine Repetabs. Convulsions, palpitations, nausea, and nervousness have been reported with pseudoephedrine overdose, a component of Narine Repetabs.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service; Telephone 91 562 04 20 indicating the medication and the amount ingested.
If you forget to take Narine Repetabs
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Unknown frequency: cannot be estimated from available data
- severe diseases that affect the blood vessels of the brain known as reversible posterior leukoencephalopathy syndrome (RPLS) and reversible cerebral vasoconstriction syndrome (RCVS)
Stop using Narine Repetabs immediately and seek urgent medical assistance if you present symptoms that may be signs of reversible posterior leukoencephalopathy syndrome (RPLS) and reversible cerebral vasoconstriction syndrome (RCVS). These include:
• sudden onset of severe headache
• discomfort
• vomiting
• confusion
• seizures
• changes in vision
The side effects that occur very frequently with Narine Repetabs (may affect more than1 in 10patients) include: insomnia.
The side effects that occur frequently with Narine Repetabs (may affect up to 1in 10patients)include: drowsiness, nervousness, drowsiness, depression, agitation, anorexia, dizziness, dry mouth, rapid heart rate, sore throat, nasal mucosa inflammation, constipation, nausea, headache, and fatigue.
The side effects that occur infrequently(may affect up to 1in 100patients)include: confusion, tremor, increased sweating, hot flashes, altered taste, abnormal tearing of the eyes, ringing in the ears, irregular heart rate, nasal bleeding, and frequent or abnormal urination and itching.
During the marketing of Narine Repetabsthe following side effects have occurred with very rarefrequencies(may affect up to 1 in 10,000patients): severe allergic reaction including rash, urticaria, and facial swelling, vertigo, seizures, abnormal heart rhythms, increased blood pressure, cough, bronchospasm, liver problems, urinary difficulties, and hair loss.
Other adverse reactions that were only reported for loratadine in clinical trials and during the post-marketing period include increased appetite, rash, and stomach discomfort.
The frequency of the following side effects is unknown:
Stop taking Narine Repetabs if these symptoms appear and contact your doctor or seek immediate medical attention.
Reporting of side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
The expiration date is the last day of the month indicated.
Composition of Narine Repetabs
Appearance of the product and content of the container
Narine Repetabs 5 mg/120 mg prolonged-release tablets are presentedin blisters in container sizes of1, 7, 10, 14, 20, 28, 30, 50, and 100 tablets.
Only some container sizes may be commercially marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Avenida Baix Llobregat, 3-5
08970 Sant Joan Despí (Barcelona)
Spain
Responsible manufacturer
SAG Manufacturing, S.L.U.
Carretera N-1, Km 36
28750, San Agustín de Guadalix (Madrid)
Spain
This medicinal product is authorized in the member states of the European Economic Area with the following names:
Austria: Clarinase
Belgium: Clarinase Repetabs
Spain: Narine Repetabs 5mg/120mg prolonged-release tablets
Greece: Clarityne-D 120/5
Portugal: Claridon
Last review date of this leaflet: 10/2024
Other sources of information
The detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.